Foscan: Phase II/III data; NDA submitted

In a European 106-patient trial, 87 percent of patients achieved a complete response (elimination of tumor), and in two separate trials, one in the U.S. and one in Europe, 58 percent of a total of 80 patients achieved a complete response. ...